Serial Convalescent Plasma Infusions for the Initial COVID-19 Infections in the Appalachian Region of West Virginia
Purpose The rapid spread of SARS-CoV-2, the virus that is responsible for causing COVID-19, has presented the medical community with another example of when convalescent plasma (CP) is still used today. The ability to standardize CP at the onset of a pandemic is unlikely to exist in a reliable and u...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2022-06-01
|
| Series: | Allergy & Rhinology |
| Online Access: | https://doi.org/10.1177/21526575221110488 |
| _version_ | 1818017434149322752 |
|---|---|
| author | Brian P. Peppers DO, PhD Aaron Shmookler MD Johnathan Stanley DO Lisa Giblin Sutton PharmD Peter L. Perrotta MD Theodore Kieffer MD David Skoner MD Stacey Mahady DO Callum Lewandrowski DO Heath Damron PhD Alexander Horspool PhD Ankit Sakhuja MBBS Paul McCarthy MD Robert W. Hostoffer DO, MSMEd |
| author_facet | Brian P. Peppers DO, PhD Aaron Shmookler MD Johnathan Stanley DO Lisa Giblin Sutton PharmD Peter L. Perrotta MD Theodore Kieffer MD David Skoner MD Stacey Mahady DO Callum Lewandrowski DO Heath Damron PhD Alexander Horspool PhD Ankit Sakhuja MBBS Paul McCarthy MD Robert W. Hostoffer DO, MSMEd |
| author_sort | Brian P. Peppers DO, PhD |
| collection | DOAJ |
| description | Purpose The rapid spread of SARS-CoV-2, the virus that is responsible for causing COVID-19, has presented the medical community with another example of when convalescent plasma (CP) is still used today. The ability to standardize CP at the onset of a pandemic is unlikely to exist in a reliable and uniformly reproducible way. We hypothesized that CP of unknown strength given in a serial manner will promote health and reduce mortality in those inflicted with COVID-19. Methods Participants were given up to 8 CP-units depending on their condition upon entry into the study and their response. Results 102 out of 117 participants were given CP. The earlier a participant received CP corelated with survival (p = 0.0004). The number of CP-units given, throughout all the clinical severities, was not significant with outcomes, p = 0.3947. A higher number of CP-units given to the severe/critical participants (without biological immunosuppressants or restrictive lung disease) did correlate with survival p = 0.0116 (2.8 vs. 2 units). Lower platelets on admission corelated with mortality. Platelet levels increase correlated with CP infusions p < 0.0001. Conclusion This study supports the serial use of CP of unknown strength based on clinical response for those infected with COVID-19. The use of 3–4 units of CP was found to be statistically significant for survival for severe and critical participants without restrictive lung disease and chronic biological immunosuppression. Increased platelet levels after CP infusions supports that CP is promoting overall health regardless of outcomes. |
| first_indexed | 2024-04-14T07:27:05Z |
| format | Article |
| id | doaj.art-18819cbe4067471dacdc0ec50c6966fe |
| institution | Directory Open Access Journal |
| issn | 2152-6567 |
| language | English |
| last_indexed | 2024-04-14T07:27:05Z |
| publishDate | 2022-06-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Allergy & Rhinology |
| spelling | doaj.art-18819cbe4067471dacdc0ec50c6966fe2022-12-22T02:05:59ZengSAGE PublishingAllergy & Rhinology2152-65672022-06-011310.1177/21526575221110488Serial Convalescent Plasma Infusions for the Initial COVID-19 Infections in the Appalachian Region of West VirginiaBrian P. Peppers DO, PhD0Aaron Shmookler MD1Johnathan Stanley DO2Lisa Giblin Sutton PharmD3Peter L. Perrotta MD4Theodore Kieffer MD5David Skoner MD6Stacey Mahady DO7Callum Lewandrowski DO8Heath Damron PhD9Alexander Horspool PhD10Ankit Sakhuja MBBS11Paul McCarthy MD12Robert W. Hostoffer DO, MSMEd13 WVU Medicine Children’s Hospital, Section of Allergy and Immunology, Morgantown, WV, USA Department of Pathology, Anatomy and Laboratory Sciences, School of Medicine, Morgantown, WV, USA , Bridgeport, WV, USA WVU Medicine, In-Patient Pharmacy, Investigational Drug Services, Morgantown, WV, USA Department of Pathology, Anatomy and Laboratory Sciences, School of Medicine, Morgantown, WV, USA Department of Pathology, Anatomy and Laboratory Sciences, School of Medicine, Morgantown, WV, USA WVU Medicine Children’s Hospital, Section of Allergy and Immunology, Morgantown, WV, USA WVU Medicine, Pediatric and Internal Medicine Residency Program, Morgantown, WV, USA WVU Medicine, Pediatric and Internal Medicine Residency Program, Morgantown, WV, USA Department of Microbiology, Immunology, and Cell Biology , Morgantown, WV, USA Department of Microbiology, Immunology, and Cell Biology , Morgantown, WV, USA WVU Medicine Division of Cardiovascular Critical Care, Dept of Cardiovascular and Thoracic Surgery, Morgantown, WV, USA WVU Medicine Division of Cardiovascular Critical Care, Dept of Cardiovascular and Thoracic Surgery, Morgantown, WV, USA Allergy-Immunology Fellowship, , OH, USAPurpose The rapid spread of SARS-CoV-2, the virus that is responsible for causing COVID-19, has presented the medical community with another example of when convalescent plasma (CP) is still used today. The ability to standardize CP at the onset of a pandemic is unlikely to exist in a reliable and uniformly reproducible way. We hypothesized that CP of unknown strength given in a serial manner will promote health and reduce mortality in those inflicted with COVID-19. Methods Participants were given up to 8 CP-units depending on their condition upon entry into the study and their response. Results 102 out of 117 participants were given CP. The earlier a participant received CP corelated with survival (p = 0.0004). The number of CP-units given, throughout all the clinical severities, was not significant with outcomes, p = 0.3947. A higher number of CP-units given to the severe/critical participants (without biological immunosuppressants or restrictive lung disease) did correlate with survival p = 0.0116 (2.8 vs. 2 units). Lower platelets on admission corelated with mortality. Platelet levels increase correlated with CP infusions p < 0.0001. Conclusion This study supports the serial use of CP of unknown strength based on clinical response for those infected with COVID-19. The use of 3–4 units of CP was found to be statistically significant for survival for severe and critical participants without restrictive lung disease and chronic biological immunosuppression. Increased platelet levels after CP infusions supports that CP is promoting overall health regardless of outcomes.https://doi.org/10.1177/21526575221110488 |
| spellingShingle | Brian P. Peppers DO, PhD Aaron Shmookler MD Johnathan Stanley DO Lisa Giblin Sutton PharmD Peter L. Perrotta MD Theodore Kieffer MD David Skoner MD Stacey Mahady DO Callum Lewandrowski DO Heath Damron PhD Alexander Horspool PhD Ankit Sakhuja MBBS Paul McCarthy MD Robert W. Hostoffer DO, MSMEd Serial Convalescent Plasma Infusions for the Initial COVID-19 Infections in the Appalachian Region of West Virginia Allergy & Rhinology |
| title | Serial Convalescent Plasma Infusions for the Initial COVID-19 Infections in the Appalachian Region of West Virginia |
| title_full | Serial Convalescent Plasma Infusions for the Initial COVID-19 Infections in the Appalachian Region of West Virginia |
| title_fullStr | Serial Convalescent Plasma Infusions for the Initial COVID-19 Infections in the Appalachian Region of West Virginia |
| title_full_unstemmed | Serial Convalescent Plasma Infusions for the Initial COVID-19 Infections in the Appalachian Region of West Virginia |
| title_short | Serial Convalescent Plasma Infusions for the Initial COVID-19 Infections in the Appalachian Region of West Virginia |
| title_sort | serial convalescent plasma infusions for the initial covid 19 infections in the appalachian region of west virginia |
| url | https://doi.org/10.1177/21526575221110488 |
| work_keys_str_mv | AT brianppeppersdophd serialconvalescentplasmainfusionsfortheinitialcovid19infectionsintheappalachianregionofwestvirginia AT aaronshmooklermd serialconvalescentplasmainfusionsfortheinitialcovid19infectionsintheappalachianregionofwestvirginia AT johnathanstanleydo serialconvalescentplasmainfusionsfortheinitialcovid19infectionsintheappalachianregionofwestvirginia AT lisagiblinsuttonpharmd serialconvalescentplasmainfusionsfortheinitialcovid19infectionsintheappalachianregionofwestvirginia AT peterlperrottamd serialconvalescentplasmainfusionsfortheinitialcovid19infectionsintheappalachianregionofwestvirginia AT theodorekieffermd serialconvalescentplasmainfusionsfortheinitialcovid19infectionsintheappalachianregionofwestvirginia AT davidskonermd serialconvalescentplasmainfusionsfortheinitialcovid19infectionsintheappalachianregionofwestvirginia AT staceymahadydo serialconvalescentplasmainfusionsfortheinitialcovid19infectionsintheappalachianregionofwestvirginia AT callumlewandrowskido serialconvalescentplasmainfusionsfortheinitialcovid19infectionsintheappalachianregionofwestvirginia AT heathdamronphd serialconvalescentplasmainfusionsfortheinitialcovid19infectionsintheappalachianregionofwestvirginia AT alexanderhorspoolphd serialconvalescentplasmainfusionsfortheinitialcovid19infectionsintheappalachianregionofwestvirginia AT ankitsakhujambbs serialconvalescentplasmainfusionsfortheinitialcovid19infectionsintheappalachianregionofwestvirginia AT paulmccarthymd serialconvalescentplasmainfusionsfortheinitialcovid19infectionsintheappalachianregionofwestvirginia AT robertwhostofferdomsmed serialconvalescentplasmainfusionsfortheinitialcovid19infectionsintheappalachianregionofwestvirginia |